Lighting The Vuse
British American Tobacco has published its new science and Innovation update, featuring the Vuse product and its latest news on tobacco harm reduction
-
by Dave Cross
Share on:
BAT says it strongly believes that generating robust, relevant and accessible scientific research is important to continue building consumer understanding and confidence in alternative tobacco and nicotine products.
“Despite the growing evidence and support from public health bodies for alternative tobacco and nicotine products, many consumers are still not aware that these products are a better alternative than smoking,” the organisation says.
The most recent Science Update focuses on the Vuse cross-sectional study, which is designed to assess and provide insights into the real-world health impact of vaping.
The study compares measures for certain biomarkers of potential harm from Vuse consumers who have been using the product for over six months with the results from smokers, former smokers and never smokers.
BAT says its study will provide further important data for the growing evidence base for the reduced-risk potential of Vuse, and the full set of findings are due to be published later this year.
Dr Sharon Goodall, BAT’s Head of Regulatory Science, said: “Our consumers want information that is easy-to-understand, accessible and reliable. To deliver this we must start with research and generate data that can then be shared with regulators, public health bodies and consumers.
“We believe that the innovative and ground-breaking research we are doing across our portfolio plays a critical role in creating understanding and confidence. This is why our regular Science Updates are so important.”
The release came at the same time as the company launched its glo™ hyper X2 heated tobacco device in Tokyo.
Kingsley Wheaton, Chief Marketing Officer at BAT, said: “The launch of glo™ hyper X2 - our newest, state-of-the-art heated tobacco product - marks another key milestone in our transformation as we build the brands of our future. Since launching our first glo™ product in Japan in 2016, we have built glo™ into a billion-dollar global brand through our deep consumer insights, science and innovation.
“Our multi-category portfolio offers the industry’s widest choice of scientifically substantiated, less risky and enjoyable products for adult smokers who are looking to switch. This is a further big step in accelerating our transformation into a consumer products business that defines itself by the consumer needs that we meet, rather than the products we sell.”
References:
- Science and Innovation update - https://www.bat-science.com/science_updateV4/index.html
Dave Cross
Journalist at POTVDave is a freelance writer; with articles on music, motorbikes, football, pop-science, vaping and tobacco harm reduction in Sounds, Melody Maker, UBG, AWoL, Bike, When Saturday Comes, Vape News Magazine, and syndicated across the Johnston Press group. He was published in an anthology of “Greatest Football Writing”, but still believes this was a mistake. Dave contributes sketches to comedy shows and used to co-host a radio sketch show. He’s worked with numerous vape companies to develop content for their websites.
Join the discussion
Harm Reduction For The Rich
The United Kingdom risks becoming a harm reduction country only for the wealthy, according to Michael Landl of the World Vapers’ Alliance
-
by Dave Cross
CAPHRA Highlights Tobacco Control Flaws
The Coalition of Asia Pacific Tobacco Harm Reduction Advocates highlights the flaws in tobacco control which has led to the rise of black market in Australia
-
by Dave Cross
A Missed Opportunity at COP10
The Smoke Free Sweden movement says that COP10 was a missed opportunity to save millions of lives
-
by Dave Cross
COP10: Promote Tobacco Harm Reduction
Experts with Smoke Free Sweden are emphasising the urgent need for a Tobacco Harm Reduction approach at COP10
-
by Dave Cross
